TNSN04169A1 - OXO-AZABICYCLIC COMPOUNDS - Google Patents
OXO-AZABICYCLIC COMPOUNDSInfo
- Publication number
- TNSN04169A1 TNSN04169A1 TNP2004000169A TNSN04169A TNSN04169A1 TN SN04169 A1 TNSN04169 A1 TN SN04169A1 TN P2004000169 A TNP2004000169 A TN P2004000169A TN SN04169 A TNSN04169 A TN SN04169A TN SN04169 A1 TNSN04169 A1 TN SN04169A1
- Authority
- TN
- Tunisia
- Prior art keywords
- group
- atom
- description
- inclusive
- integer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un composé choisi parmi ceux de formule (I) Dans laquelle : X1; X2 et X3 représentent des atomes de N ou des groupes –CR3 dans lesquels R3 est tel que défini dans la description; G1 représente un groupe choisi parmi ceux de formules (i/a) et (i/b) dans lesquelles R4; R5 et R6 sont tels que définis dans la description; G2 représente un groupe choisi entre un triple liaison carbone-carbone; un groupe –CH=C=CH-; un groupe C=O; groupe C=S; un groupe S(O)n; dans lequel n1 représente un nombre entier de 0 à 2 inclus; ou un groupe de formule (i/c) dans laquelle Y1 représente un atome de 0; un atome de S; un groupe –NH ou un groupe –N-alkyle; et Y2 représente un atome de 0; un atome de S; un groupe –NH; ou un groupe –N alkyle; n représente un nombre entier de 0 à 6 inclus et m représente un nombre entier de 0 à 7 inclus; Z1 représente un groupe – CR9 R10; dans lequel R9 et R10 sont tels que définis dans la description; A représente un système cyclique; R1 représente un groupe choisi entre H; des groupes alkyle; alcényle et alcynyle facultativement substitués et le groupe de formule (i/d) dans laquelle p; Z2; B; q et G3 sont tels que définis dans la description et; facultativement; ses isomères optiques; son N-oxyde et ses sels d'addition formés avec un acide ou une base pharmaceutiquement acceptable; et des produits médicamenteux le contenant sont utiles comme inhibiteurs spécifiques de la métalloprotéase de matrice de type 13.A compound selected from those of formula (I) wherein: X1; X 2 and X 3 represent N atoms or -CR 3 groups in which R 3 is as defined in the description; G1 represents a group selected from those of formulas (i / a) and (i / b) in which R4; R5 and R6 are as defined in the description; G2 represents a group selected from a carbon-carbon triple bond; a group -CH = C = CH-; a group C = O; group C = S; a group S (O) n; wherein n1 is an integer from 0 to 2 inclusive; or a group of formula (i / c) wherein Y1 represents an atom of 0; an atom of S; an -NH group or a -N-alkyl group; and Y2 represents an atom of 0; an atom of S; a group -NH; or a -N alkyl group; n represents an integer from 0 to 6 inclusive and m represents an integer from 0 to 7 inclusive; Z1 represents a group - CR9 R10; wherein R9 and R10 are as defined in the description; A represents a ring system; R1 represents a group selected from H; alkyl groups; optionally substituted alkenyl and alkynyl and the group of formula (i / d) wherein p; Z2; B; q and G3 are as defined in the description and; optionally; its optical isomers; its N-oxide and its addition salts formed with a pharmaceutically acceptable acid or base; and drug products containing it are useful as specific inhibitors of type 13 matrix metalloprotease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/003240 WO2003076416A1 (en) | 2002-03-08 | 2002-03-08 | Oxo azabicyclic compounds |
| PCT/EP2003/002277 WO2003076417A2 (en) | 2002-03-08 | 2003-03-06 | Oxo-azabicyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN04169A1 true TNSN04169A1 (en) | 2007-03-12 |
Family
ID=27798761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2004000169A TNSN04169A1 (en) | 2002-03-08 | 2004-09-03 | OXO-AZABICYCLIC COMPOUNDS |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1492775A2 (en) |
| JP (1) | JP2005526070A (en) |
| KR (1) | KR20040095270A (en) |
| CN (1) | CN1738806A (en) |
| AP (1) | AP2004003125A0 (en) |
| AR (1) | AR039562A1 (en) |
| AU (2) | AU2002249275A1 (en) |
| BR (1) | BR0308280A (en) |
| CA (1) | CA2478706A1 (en) |
| CO (1) | CO5601020A2 (en) |
| EA (1) | EA200401053A1 (en) |
| EC (1) | ECSP045278A (en) |
| IL (1) | IL163818A0 (en) |
| IS (1) | IS7414A (en) |
| MA (1) | MA27183A1 (en) |
| MX (1) | MXPA04008681A (en) |
| NO (1) | NO20044041L (en) |
| OA (1) | OA12782A (en) |
| PA (1) | PA8568501A1 (en) |
| PE (1) | PE20031018A1 (en) |
| PL (1) | PL372622A1 (en) |
| SV (1) | SV2003001495A (en) |
| TN (1) | TNSN04169A1 (en) |
| UY (1) | UY27700A1 (en) |
| WO (2) | WO2003076416A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539501A1 (en) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | TRIAZOLO COMPOUNDS AS MMP INHIBITORS |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| BR0313385A (en) | 2002-08-13 | 2005-06-14 | Warner Lambert Co | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| MXPA05001603A (en) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Monocyclic derivatives as matrix metalloproteinase inhibitors. |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| PA8578101A1 (en) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS |
| JP2006504665A (en) | 2002-08-13 | 2006-02-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| AU2003253150A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| DE10360835A1 (en) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis |
| RU2006142305A (en) * | 2004-04-30 | 2008-06-10 | Такеда Фармасьютикал Компани Лимитед (Jp) | HETEROCYCLIC AMIDE COMPOUND AND ITS APPLICATION AS MMP-3 INHIBITOR |
| BRPI0512075A (en) * | 2004-06-15 | 2008-02-06 | Astrazeneca Ab | compound, process for the preparation thereof, pharmaceutical composition, use of a compound, and methods for producing a b-raf inhibiting effect, and an anticancer effect on a warm-blooded animal, and for treating a disease |
| US7732453B2 (en) | 2006-10-05 | 2010-06-08 | Gilead Palo Alto, Inc. | Pyrido[2,3-B] pyrazin-3(4H)-ones for use as stearoyl CoA desaturase inhibitors |
| AR083475A1 (en) | 2010-10-18 | 2013-02-27 | Merz Pharma Gmbh & Co Kgaa | METABOTROPIC GLUTAMATE RECEIVERS MODULATORS |
| CN103524431B (en) * | 2013-09-24 | 2016-01-13 | 西安交通大学 | 3-benzyl-4-quianzolinones and synthetic method thereof and application |
| JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
| WO2017050864A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | New compounds |
| ES2904513T3 (en) | 2015-09-23 | 2022-04-05 | Janssen Pharmaceutica Nv | Biheteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| FR3046793B1 (en) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | NOVEL PHOSPHINAN DERIVATIVES AND AZAPHOSPHINANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0946095A1 (en) * | 1996-12-17 | 1999-10-06 | E.I. Du Pont De Nemours And Company | Fungicidal quinazolinones |
| PA8539401A1 (en) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | QUINAZOLINAS AS INHIBITORS OF MMP-13 |
| PA8539301A1 (en) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX |
-
2002
- 2002-03-08 WO PCT/EP2002/003240 patent/WO2003076416A1/en not_active Application Discontinuation
- 2002-03-08 AU AU2002249275A patent/AU2002249275A1/en not_active Abandoned
-
2003
- 2003-03-04 SV SV2003001495A patent/SV2003001495A/en not_active Application Discontinuation
- 2003-03-06 WO PCT/EP2003/002277 patent/WO2003076417A2/en not_active Application Discontinuation
- 2003-03-06 EA EA200401053A patent/EA200401053A1/en unknown
- 2003-03-06 EP EP03708181A patent/EP1492775A2/en not_active Withdrawn
- 2003-03-06 PL PL03372622A patent/PL372622A1/en not_active Application Discontinuation
- 2003-03-06 IL IL16381803A patent/IL163818A0/en unknown
- 2003-03-06 MX MXPA04008681A patent/MXPA04008681A/en unknown
- 2003-03-06 AP APAP/P/2004/003125A patent/AP2004003125A0/en unknown
- 2003-03-06 UY UY27700A patent/UY27700A1/en not_active Application Discontinuation
- 2003-03-06 PA PA20038568501A patent/PA8568501A1/en unknown
- 2003-03-06 AU AU2003212307A patent/AU2003212307A1/en not_active Abandoned
- 2003-03-06 KR KR10-2004-7013994A patent/KR20040095270A/en not_active Application Discontinuation
- 2003-03-06 BR BR0308280-6A patent/BR0308280A/en not_active IP Right Cessation
- 2003-03-06 CA CA002478706A patent/CA2478706A1/en not_active Abandoned
- 2003-03-06 OA OA1200400234A patent/OA12782A/en unknown
- 2003-03-06 CN CNA038048752A patent/CN1738806A/en active Pending
- 2003-03-06 AR ARP030100749A patent/AR039562A1/en not_active Application Discontinuation
- 2003-03-06 PE PE2003000218A patent/PE20031018A1/en not_active Application Discontinuation
- 2003-03-06 JP JP2003574636A patent/JP2005526070A/en not_active Withdrawn
-
2004
- 2004-08-19 IS IS7414A patent/IS7414A/en unknown
- 2004-08-25 CO CO04082792A patent/CO5601020A2/en not_active Application Discontinuation
- 2004-08-31 MA MA27842A patent/MA27183A1/en unknown
- 2004-09-03 TN TNP2004000169A patent/TNSN04169A1/en unknown
- 2004-09-03 EC EC2004005278A patent/ECSP045278A/en unknown
- 2004-09-24 NO NO20044041A patent/NO20044041L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0308280A (en) | 2004-12-28 |
| CN1738806A (en) | 2006-02-22 |
| AR039562A1 (en) | 2005-02-23 |
| CA2478706A1 (en) | 2003-09-18 |
| PL372622A1 (en) | 2005-07-25 |
| AP2004003125A0 (en) | 2004-09-30 |
| MA27183A1 (en) | 2005-01-03 |
| JP2005526070A (en) | 2005-09-02 |
| NO20044041L (en) | 2004-10-07 |
| UY27700A1 (en) | 2003-10-31 |
| CO5601020A2 (en) | 2006-01-31 |
| WO2003076417A3 (en) | 2003-11-13 |
| IL163818A0 (en) | 2005-12-18 |
| EP1492775A2 (en) | 2005-01-05 |
| IS7414A (en) | 2004-08-19 |
| OA12782A (en) | 2006-07-10 |
| PE20031018A1 (en) | 2004-01-09 |
| WO2003076416A1 (en) | 2003-09-18 |
| AU2002249275A1 (en) | 2003-09-22 |
| EA200401053A1 (en) | 2005-04-28 |
| MXPA04008681A (en) | 2004-12-06 |
| ECSP045278A (en) | 2004-10-26 |
| WO2003076417A2 (en) | 2003-09-18 |
| KR20040095270A (en) | 2004-11-12 |
| AU2003212307A1 (en) | 2003-09-22 |
| PA8568501A1 (en) | 2003-12-19 |
| SV2003001495A (en) | 2003-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN04169A1 (en) | OXO-AZABICYCLIC COMPOUNDS | |
| HUP0203700A2 (en) | N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents and pharmaceutical compositions containing them | |
| CA2481461A1 (en) | Derivatives of n-[phenyl(piperidin-2-yl) methyl] benzamide, the preparation method thereof and application of same in therapeutics | |
| MA30014B1 (en) | SPIROCYCLIC DERIVATIVES | |
| HUP0401889A2 (en) | 1,8-naphthyridine derivatives as antidiabetics and pharmaceutical compositions containing them | |
| CA2394086A1 (en) | 4-aminopiperidine derivatives and their use as medicine | |
| TNSN04156A1 (en) | SUBSTITUTED PYRIDINONES AS MODULATORS OF MAP-KINASE P38 | |
| TNSN05073A1 (en) | NOVEL SPIROCONDENSE QUINAZOLINONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | |
| MA27390A1 (en) | DIOXANE-2-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
| KR900012906A (en) | N-phenyl-N- (4-piperidinyl) amide useful as an analgesic | |
| EP0343900A3 (en) | Piperazine compounds | |
| TNSN05172A1 (en) | ARYLALKYLCARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
| MA28742B1 (en) | PYRIDO-PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION | |
| MA27887A1 (en) | SUBSTITUTED DICETOPIPERAZINES AND THEIR USE AS ANTAGONISTS OF OCYTOCIN | |
| TNSN07145A1 (en) | 2-AMIDO-4-PHENYLTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | |
| MA31674B1 (en) | Derivatives of 7-alkynil-1,8-naviteredone prepared and therapeutic uses | |
| MA27197A1 (en) | SALTS OF TOLTERODINE | |
| MA27712A1 (en) | TRIAZOLES USEFUL IN THERAPEUTICS | |
| MA27795A1 (en) | CYCLIC AMINE DERIVATIVES, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| MA27492A1 (en) | NOVEL ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| EP0262053A3 (en) | Amino-acid derivatives, their preparation and pharmaceutical compositions containing them | |
| MA27260A1 (en) | New 3- (4-oxo-4H-chromen-2-yl) - (1H) -quinoline-4-ones derivatives, process for their preparation and pharmaceutical compositions containing them | |
| TNSN08237A1 (en) | SPIROCYCLIC DERIVATIVES | |
| MA27947A1 (en) | 2-SUBSTITUTED PYRIMIDINES | |
| MA27545A1 (en) | New fluorinated benzothiadiazine derivatives, process for their preparation and pharmaceutical compositions containing them |